Printer Friendly

U.S. PATENT OFFICE GRANTS PATENT ON DRUG DELIVERY APPLICATOR

 SAN DIEGO, July 19 /PRNewswire/ -- Lois Crandell, president and chief executive officer of BTX Inc., announced that the U.S. Patent and Trademark Office has allowed a patent application for "Injection and Electroporation Apparatus for Drug and Gene Delivery." Covered in the patent is a needle-array electrode applicator which is in the design phase of development. The applicator will be used in the treatment of pancreatic cancer.
 In this design, an array of electrodes is used to access the tumor through the stomach and into the pancreas. The drug can be injected systemically, or through the needles. The needles serve as electrodes which allow a pulsed electric field to open pores in a cancer cell allowing the anti-cancer drug to directly enter the cell. This is one of the applications of Electrochemotherapy(R).
 Electrochemotherapy is the process of delivering anti-cancer drugs into cancer cells using pulsed electric fields. Researchers have already demonstrated that this technique may allow drug doses to be reduced with subsequent reduction in toxic side effects.
 This is the first patent application granted to BTX for a drug/gene applicator to be used in the treatment of cancer. Patents are pending that relate to Electrochemotherapy and the use of applicators for the treatment of other types of cancers.
 BTX is regarded as the pioneer and technological leader in the broad, enabling technology of Electroporation, a technique of physically introducing drugs or DNA into cells via pulsed electric fields. Founded in 1983, BTX has successfully introduced 16 electroporation-related products for in vitro use in the research laboratory. The company is currently developing and testing drug delivery systems for treating certain cancers and preventing restenosis. BTX drug and gene delivery systems will ultimately provide broadly effective methods of treating cancer, heart disease and will eventually contribute to combating genetic diseases.
 -0- 7/19/93
 /CONTACT: Christie S. Featherstone, director of corporate communications of BTX, 619-597-6006/


CO: BTX Inc. ST: California IN: MTC SU: PDT

MF-JL -- SD003 -- 2851 07/19/93 07:54 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 19, 1993
Words:334
Previous Article:QUALCOMM REPORTS 81 PERCENT REVENUE INCREASE AND NET EARNINGS FOR THIRD QUARTER
Next Article:MENTOR GRAPHICS CORP. TO OFFER 'PRONTO-ON-CALL' FAX INFORMATION SERVICE TO THE INVESTMENT COMMUNITY AND THE MEDIA
Topics:


Related Articles
PHARMOS CORPORATION'S NOVEL OCULAR DRUG DELIVERY SYSTEM RECEIVES ADDITIONAL PATENT
ARADIGM AWARDED PATENT COVERING FLOW SENSING TECHNOLOGY FOR ITS PULMONARY DRUG DELIVERY SYSTEMS
ARADIGM AWARDED TWO PATENTS ON ITS PULMONARY DRUG DELIVERY TECHNOLOGY
Emisphere Receives Notice of Allowance for Patent on Novel Family of Carriers
Aradigm Receives Two New U.S. Patents On AERx(TM) Pulmonary Drug Delivery System
Genetronics announces issuance of electroporation technology patents.
Generex Biotechnology announces grant of European patent for aerosol delivery.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters